Biomarkers for Assessing Peripheral Neuropathy Response to Cancer Treatment
AssigneeJanssen Pharmaceutica NV
InventorsNadine Cohen, Reyna Favis, Qingqin Li, Deborah Ricci, Yu Sun, Helgi van de Velde
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.
Claims17
A method for identifying whether a patient is at increased risk for developing an adverse neurological event in respond to a cancer treatment, comprising:
- determining whether or not said patient possesses one or more biomarkers for said increased risk, wherein the presence of said biomarker indicates an increased risk for said adverse neurological event.
A diagnostic kit or equivalent for identifying patients likely to develop an adverse event in response to treatment for cancer, comprising:
- a biomarker selected from the group consisting of one or more of the sequence variances in the candidate genes listed in Appendix 1;
- and instructions for employing said biomarker to identify patients likely to develop peripheral neuropathy in response to treatment for cancer.
A method for treating a patient for cancer comprising:
- determining whether or not said patient possesses one or more biomarkers for increased risk of developing an adverse neurological event in response to a cancer treatment, wherein the presence of said biomarker indicates an increased risk for said adverse neurological event;
- and selecting a first method of treatment or a second method of treatment, wherein said first method of treatment and second method of treatment are dependent on whether said patient is likely to develop peripheral neuropathy in response to said treatment for cancer.
A method for selecting a patient for administration of a method of treatment for cancer, comprising:
- comparing a presence or absence of at least one biomarker selected from the group consisting of one or more of the sequence variances in the candidate genes listed in Appendix 1 in cells of said patient with a list of variances, wherein the presence of at least one variance is indicative that said method of treatment for cancer may be deleterious to said patient, and modifying said method of treatment for cancer if said at least one variance is present in said patient's cells.
Dependencies are inferred from the claim text.